Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Non-phase study NCT06662162

Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration

Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration — Recruiting • Non-phase study • NCT06662162.

📅 11 Aug 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT06662162
Start
2025-05-07
Completion
2027-03-31
ClinicaliQ Trial Snapshot
  • Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration — Recruiting • Non-phase study • NCT06662162.
  • A trial testing whether a microcurrent stimulation device applied through the eyelid safely improves vision in intermediate-to-advanced dry age-related macular degeneration.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The goal of this clinical trial is to characterize the safety and effectiveness of the i-Lumen AMD transpalpebral microcurrent device and therapy in patients with intermediate to advanced nonexudative AMD. Participants will: * Undergo an initial loading regimen, followed by 7 maintenance over the course of 11 months. * Participants will return monthly through Month 14 (3 months post-last treatment) for evaluation and monitoring. Conditions: Age-Related Macular Degeneration, Age-related Macular Degeneration (ARMD), Intermediate AMD, Geographic Atrophy Secondary to Age-related Macular Degeneration Interventions: i-Lumen AMD Lead Sponsor: i-Lumen Scientific AUS PTY…

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn